Journal article
Kidney Function Following COVID-19 in Children and Adolescents
JAMA network open, Vol.8(4), e254129
04/01/2025
DOI: 10.1001/jamanetworkopen.2025.4129
PMCID: PMC11992607
PMID: 40214993
Abstract
It remains unclear whether children and adolescents with SARS-CoV-2 infection are at heightened risk for long-term kidney complications.
To investigate whether SARS-CoV-2 infection is associated with an increased risk of postacute kidney outcomes among pediatric patients, including those with preexisting kidney disease or acute kidney injury (AKI).
This retrospective cohort study used data from 19 health institutions in the National Institutes of Health Researching COVID to Enhance Recovery (RECOVER) initiative from March 1, 2020, to May 1, 2023 (follow-up ≤2 years completed December 1, 2024; index date cutoff, December 1, 2022). Participants included children and adolescents (aged <21 years) with at least 1 baseline visit (24 months to 7 days before the index date) and at least 1 follow-up visit (28 to 179 days after the index date).
SARS-CoV-2 infection, determined by positive laboratory test results (polymerase chain reaction, antigen, or serologic) or relevant clinical diagnoses. A comparison group included children with documented negative test results and no history of SARS-CoV-2 infection.
Outcomes included new-onset chronic kidney disease (CKD) stage 2 or higher or CKD stage 3 or higher among those without preexisting CKD; composite kidney events (≥50% decline in estimated glomerular filtration rate [eGFR], eGFR ≤15 mL/min/1.73 m2, dialysis, transplant, or end-stage kidney disease diagnosis), and at least 30%, 40%, or 50% eGFR decline among those with preexisting CKD or acute-phase AKI. Hazard ratios (HRs) were estimated using Cox proportional hazards regression models with propensity score stratification.
Among 1 900 146 pediatric patients (487 378 with and 1 412 768 without COVID-19), 969 937 (51.0%) were male, the mean (SD) age was 8.2 (6.2) years, and a range of comorbidities was represented. SARS-CoV-2 infection was associated with higher risk of new-onset CKD stage 2 or higher (HR, 1.17; 95% CI, 1.12-1.22) and CKD stage 3 or higher (HR, 1.35; 95% CI, 1.13-1.62). In those with preexisting CKD, COVID-19 was associated with an increased risk of composite kidney events (HR, 1.15; 95% CI, 1.04-1.27) at 28 to 179 days. Children with acute-phase AKI had elevated HRs (1.29; 95% CI, 1.21-1.38) at 90 to 179 days for composite outcomes.
In this large US cohort study of children and adolescents, SARS-CoV-2 infection was associated with a higher risk of adverse postacute kidney outcomes, particularly among those with preexisting CKD or AKI, suggesting the need for vigilant long-term monitoring.
Details
- Title: Subtitle
- Kidney Function Following COVID-19 in Children and Adolescents
- Creators
- Lu Li - University of PennsylvaniaTing Zhou - University of PennsylvaniaYiwen Lu - University of PennsylvaniaJiajie Chen - University of PennsylvaniaYuqing Lei - University of PennsylvaniaQiong Wu - University of PittsburghJonathan Arnold - University of Pittsburgh School of MedicineMichael J Becich - University of Pittsburgh School of MedicineYuriy Bisyuk - University Medical Center New OrleansSaul Blecker - New York UniversityElizabeth Chrischilles - University of IowaDimitri A Christakis - Seattle Children's HospitalCarol Reynolds Geary - University of Nebraska Medical CenterRavi Jhaveri - Lurie Children's HospitalLeslie Lenert - Medical University of South CarolinaMei Liu - University of FloridaParsa Mirhaji - Albert Einstein College of MedicineHiroki Morizono - Children's NationalRuby Patel - Stanford MedicineAbu S M Mosa - University of MissouriWilliam E Smoyer - The Ohio State UniversityAli Mirza Onder - Division of Pediatric Nephrology, Nemours Children's Hospital, Wilmington, DelawareBradley W Taylor - Medical College of WisconsinDavid A Williams - University of MichiganBradley P Dixon - University of Colorado Anschutz Medical CampusJoseph T Flynn - Seattle Children's HospitalCaroline Gluck - Division of Pediatric Nephrology, Nemours Children's Health, Wilmington, DelawareLyndsay A Harshman - University of IowaMark M Mitsnefes - University of CincinnatiZubin J Modi - University of MichiganCynthia G Pan - Medical College of WisconsinHiren P Patel - The Ohio State UniversityPriya S Verghese - Northwestern UniversityChristopher B Forrest - Children's Hospital of PhiladelphiaMichelle R Denburg - University of PennsylvaniaYong Chen - University of PennsylvaniaResearching COVID to Enhance Recovery (RECOVER) Consortium
- Resource Type
- Journal article
- Publication Details
- JAMA network open, Vol.8(4), e254129
- DOI
- 10.1001/jamanetworkopen.2025.4129
- PMID
- 40214993
- PMCID
- PMC11992607
- NLM abbreviation
- JAMA Netw Open
- ISSN
- 2574-3805
- eISSN
- 2574-3805
- Publisher
- AMER MEDICAL ASSOC; CHICAGO
- Grant note
- NIH: OTA OT2HL161847-01
This research was funded by agreement OTA OT2HL161847-01 from the NIH as part of the Researching COVID to Enhance Recovery (RECOVER) research initiative.
- Language
- English
- Date published
- 04/01/2025
- Academic Unit
- Pharmacy; Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Epidemiology; Iowa Neuroscience Institute; Radiation Oncology
- Record Identifier
- 9984808527902771
Metrics
6 Record Views